我們已在上線！進一步了解

HUTCHMED

HCM

市值 US$24.4億

14.05 USD

+0.11

0.79%

收盤時已更新 10月16日下午4:00 EDT

1天

0.79%

5天

0.36%

1個月

4.38%

3個月

21.02%

6個月

-8.53%

今年迄今

2.93%

1年

-8.77%

5年

-56.53%

10年

23.35%

關於： HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.

員工： 1,796

醫療保健藥品製造商－特殊及學名藥

新聞

正面

中性

負面

市場情緒 3個月

正面 47.4%

中性 47.4%

負面 5.3%

24/7 Wall Street

ADP Warns of Cooling Labor Market While Its Own Business Feels the Chill

ADP publishes the jobs data Wall Street watches every month, but its own payroll counts now tell a different story about where the labor market is actually heading.

ADP Warns of Cooling Labor Market While Its Own Business Feels the Chill

AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination

HUTCHMED (China) said on Tuesday Anglo-Swedish ‌drugmaker AstraZeneca had filed an application with the US ⁠Food and Drug Administration for approval of the ORPATHYS-TAGRISSO combination in patients with ‌advanced ⁠lung cancer.

AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination

HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer

— Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after progression on an EGFR-TKI therapy —

HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer

HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 27, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Phase Ia part of a global clinical trial of HMPL-A830 in patients with unresectable, advanced or metastatic solid tumors.

HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology (“ESMO”) Congress 2026, taking place on October 23-27, 2026, in Madrid, Spain.

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026

HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy

HUTCHMED NASDAQ: HCM said it has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, or ATTC. The transaction has a total potential value of approximately $1.3 billion, including a $110 million upfront payment, according to Acting Chief Executive Officer and Chief Financial Officer Johnny Cheng.

HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy

HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 Transcript

HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 Transcript

HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 Transcript

Proactive Investors

Panmure and Cavendish reiterate buy on Hutchmed after GSK deal

Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) won ringing endorsements from City brokers on Thursday after securing a blockbuster licensing agreement with GSK PLC (LSE:GSK, NYSE:GSK), exposing what analysts regard as a deep valuation disconnect. The shares leapt 15% to 205.84p as Cavendish and Panmure Liberum reiterated their respective 'buy' ratings, arguing that the market continues to overlook the biotech's expanding oncology pipeline.

Panmure and Cavendish reiterate buy on Hutchmed after GSK deal

Proactive Investors

HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal

Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares jumped 17% to 210p on Thursday after the oncology specialist struck a licensing agreement with GSK worth up to US$1.295 billion for its experimental KRAS-EGFR cancer therapy. The shares were up 30.5p from Wednesday's 179.5p close following news that GSK will receive exclusive rights outside Mainland China, Hong Kong, Macau and Taiwan to develop and commercialise HMPL-A830.

HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal

HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug

GSK subsidiary GlaxoSmithKline Intellectual Property (No. 4) Ltd will pay ‌a unit of HUTCHMED (China) $110 million upfront for rights to an experimental drug for solid tumours, the Chinese drugmaker said on Thursday.

HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug

查看新聞排名

價格圖表採用Lightweight Charts™實作